This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Value Investors Buy Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Here's How Much a $1000 Investment in Tenet Healthcare Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
HCA Healthcare Stock Up 12.7% in 6 Months: What Should Investors Do?
by Zubia Masood
HCA is expected to benefit from growing volumes and operational efficiency. However, declining outpatient surgeries and the impact of hurricanes might partially offset the positives.
Pediatrix Medical Stock Soars 30.5% Since Q3 Earnings Beat
by Zacks Equity Research
MD expects transformational and restructuring-related expenses to be $48 million in 2024.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Tenet (THC) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Tenet (THC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Tenet Stock Jumps 19.6% Since Q3 Results: What Should Investors Do?
by Kaibalya Pravo Dey
THC continues to experience strong demand for its services, which is expected to continue throughout the year.
Tenet Healthcare and Starbucks have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tenet Healthcare and Starbucks are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Tenet Healthcare (THC)
by Derek Lewis
Tenet Healthcare shares have been scorching-hot in 2024, up 115% and outperforming many of the Mag 7 members.
Teladoc Health Q3 Loss Narrows on Strong Integrated Care Unit
by Zacks Equity Research
TDOC expects 2024 U.S. Integrated Care Members to remain within 93.5-94.5 million.
The Zacks Analyst Blog Highlights XLV, Tenet Healthcare, PKB and Dycom Industries
by Zacks Equity Research
XLV, Tenet Healthcare, PKB and Dycom Industries are part of the Zacks top Analyst Blog.
Tenet (THC) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Tenet (THC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Analyzing Universal Health's Q3 Earnings: To Buy or Keep Your Cool?
by Debasmita Chatterjee
UHS is well-poised to benefit from growing patient volumes and extensive treatment network, partly offset by elevated operating costs.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Sector ETFs & Stocks Likely to Benefit Despite Soft October Jobs Data
by Sanghamitra Saha
The U.S. economy added 12,000 jobs in October, down sharply from September and below the Dow Jones estimate for 100,000.
Tenet Q3 Earnings Beat on Strong Ambulatory Unit, '24 EPS View Raised
by Zacks Equity Research
THC's Q3 results benefit from higher same-hospital admissions and Medicaid supplemental revenue gains. Cost-cutting measures help offset challenges from hospital divestitures.
Play Likely Earnings Beat With 4 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Tenet Healthcare (THC), Fortinet (FTNT), Leidos (LDOS) and American Airlines (AAL) are likely to beat on the bottom line in their upcoming releases.
New Strong Buy Stocks for November 1st
by Zacks Equity Research
SKY, AAT, SOHO, THC and LDOS have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2024.
Zacks Investment Ideas feature highlights: Pfizer, Philip Morris and Tenet Healthcare
by Zacks Equity Research
Pfizer, Philip Morris and Tenet Healthcare are part of the Zacks Investment Ideas article.
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Buy, Hold or Sell HCA Healthcare Stock After Q3 Earnings?
by Zubia Masood
HCA is poised to benefit from volume growth and expansion initiatives.
Humana Q3 Earnings Beat on Growing Premiums & Cost Management
by Zacks Equity Research
Better-than-expected Medicare Advantage membership aids HUM's third-quarter results.
3 Stocks to Buy Following Robust Quarterly Results
by Derek Lewis
Throughout the Q3 reporting cycle, several companies, including Pfizer, Philip Morris, and Tenet Healthcare, have stolen the spotlight, with each raising guidance.